These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33277582)

  • 1. The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus.
    Pijet B; Konopka A; Rejmak E; Stefaniuk M; Khomiak D; Bulska E; Pikul S; Kaczmarek L
    Sci Rep; 2020 Dec; 10(1):21314. PubMed ID: 33277582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stepwise candidate drug screening for myopia control by using zebrafish, mouse, and Golden Syrian Hamster myopia models.
    Lin MY; Lin IT; Wu YC; Wang IJ
    EBioMedicine; 2021 Mar; 65():103263. PubMed ID: 33691248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The matrix metalloproteinase inhibitor marimastat promotes neural progenitor cell differentiation into neurons by gelatinase-independent TIMP-2-dependent mechanisms.
    Sinno M; Biagioni S; Ajmone-Cat MA; Pafumi I; Caramanica P; Medda V; Tonti G; Minghetti L; Mannello F; Cacci E
    Stem Cells Dev; 2013 Feb; 22(3):345-58. PubMed ID: 23098139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical role for matrix metalloproteinases in liver regeneration.
    Alwayn IP; Verbesey JE; Kim S; Roy R; Arsenault DA; Greene AK; Novak K; Laforme A; Lee S; Moses MA; Puder M
    J Surg Res; 2008 Apr; 145(2):192-8. PubMed ID: 18222481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects.
    Broekaart DW; Bertran A; Jia S; Korotkov A; Senkov O; Bongaarts A; Mills JD; Anink JJ; Seco J; Baayen JC; Idema S; Chabrol E; Becker AJ; Wadman WJ; Tarragó T; Gorter JA; Aronica E; Prades R; Dityatev A; van Vliet EA
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33141761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of metal ions and Marimastat with matrix metalloproteinase 9.
    Underwood CK; Min D; Lyons JG; Hambley TW
    J Inorg Biochem; 2003 Jun; 95(2-3):165-70. PubMed ID: 12763661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.
    Engel T; Martinez-Villarreal J; Henke C; Jimenez-Mateos EM; Sanz-Rodriguez A; Alves M; Hernandez-Santana Y; Brennan GP; Kenny A; Campbell A; Lucas JJ; Henshall DC
    Mol Neurodegener; 2017 Feb; 12(1):21. PubMed ID: 28235423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High concordance between hippocampal transcriptome of the mouse intra-amygdala kainic acid model and human temporal lobe epilepsy.
    Conte G; Parras A; Alves M; Ollà I; De Diego-Garcia L; Beamer E; Alalqam R; Ocampo A; Mendez R; Henshall DC; Lucas JJ; Engel T
    Epilepsia; 2020 Dec; 61(12):2795-2810. PubMed ID: 33070315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and function of the metabotropic purinergic P2Y receptor family in experimental seizure models and patients with drug-refractory epilepsy.
    Alves M; Gomez-Villafuertes R; Delanty N; Farrell MA; O'Brien DF; Miras-Portugal MT; Hernandez MD; Henshall DC; Engel T
    Epilepsia; 2017 Sep; 58(9):1603-1614. PubMed ID: 28733972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct behavioral and epileptic phenotype differences in 129/P mice compared to C57BL/6 mice subject to intraamygdala kainic acid-induced status epilepticus.
    Almeida Silva LF; Engel T; Reschke CR; Conroy RM; Langa E; Henshall DC
    Epilepsy Behav; 2016 Nov; 64(Pt A):186-194. PubMed ID: 27744244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice.
    Kimata M; Otani Y; Kubota T; Igarashi N; Yokoyama T; Wada N; Yoshimizu N; Fujii M; Kameyama K; Okada Y; Kumai K; Kitajima M
    Jpn J Cancer Res; 2002 Jul; 93(7):834-41. PubMed ID: 12149150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
    Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ
    J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatio-temporally restricted blood-brain barrier disruption after intra-amygdala kainic acid-induced status epilepticus in mice.
    Michalak Z; Sano T; Engel T; Miller-Delaney SF; Lerner-Natoli M; Henshall DC
    Epilepsy Res; 2013 Feb; 103(2-3):167-79. PubMed ID: 23182415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats I: Magnetic resonance imaging.
    van Vliet EA; Otte WM; Wadman WJ; Aronica E; Kooij G; de Vries HE; Dijkhuizen RM; Gorter JA
    Epilepsia; 2016 Jan; 57(1):59-69. PubMed ID: 26691904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exclusive Activation of Caspase-3 in Mossy Fibers and Altered Dynamics of Autophagy Markers in the Mice Hippocampus upon Status Epilepticus Induced by Kainic Acid.
    Rami A; Benz A
    Mol Neurobiol; 2018 May; 55(5):4492-4503. PubMed ID: 28685385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippocampal damage after intra-amygdala kainic acid-induced status epilepticus and seizure preconditioning-mediated neuroprotection in SJL mice.
    Tanaka K; Jimenez-Mateos EM; Matsushima S; Taki W; Henshall DC
    Epilepsy Res; 2010 Feb; 88(2-3):151-61. PubMed ID: 19931419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats II: Potential mechanisms.
    van Vliet EA; Otte WM; Wadman WJ; Aronica E; Kooij G; de Vries HE; Dijkhuizen RM; Gorter JA
    Epilepsia; 2016 Jan; 57(1):70-8. PubMed ID: 26691741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix Metalloproteinase-Mediated Blood-Brain Barrier Dysfunction in Epilepsy.
    Rempe RG; Hartz AMS; Soldner ELB; Sokola BS; Alluri SR; Abner EL; Kryscio RJ; Pekcec A; Schlichtiger J; Bauer B
    J Neurosci; 2018 May; 38(18):4301-4315. PubMed ID: 29632167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cav3.1 T-type calcium channel modulates the epileptogenicity of hippocampal seizures in the kainic acid-induced temporal lobe epilepsy model.
    Kim CH
    Brain Res; 2015 Oct; 1622():204-16. PubMed ID: 26111648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Hydroxypyrone-Based Inhibitor of Metalloproteinase-12 Displays Neuroprotective Properties in Both
    Vinet J; Costa AM; Salinas-Navarro M; Leo G; Moons L; Arckens L; Biagini G
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30044455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.